In vitro assessment of apheresis and pooled buffy coat platelet components suspended in plasma and SSP+ photochemically treated with amotosalen and UVA for pathogen inactivation (INTERCEPT Blood System™)

Vox Sang. 2011 Feb;100(2):247-9. doi: 10.1111/j.1423-0410.2010.01389.x. Epub 2010 Aug 24.

Abstract

Background and objectives: INTERCEPT Blood System™ is a pathogen inactivation system for blood components. The initial approval required a platelet component to be suspended in a combination of plasma and Platelet additive Solution/PAS-III. Improved platelet storage has been reported with Mg++ and K+ supplementation (PAS-IIIM). This study validated the use of INTERCEPT™/PAS-IIIM for apheresis and pooled buffy-coat platelet components.

Materials and methods: The platelet dose and pH throughout 5 days of storage met the European and French requirements for quality standards.

Results and conclusion: Additional metabolic and activation assessments of the treated platelets confirmed the previously reported superiority of PAS-IIIM over PAS-III, but extended it to the INTERCEPT™ process.

MeSH terms

  • Blood Component Removal*
  • Blood Platelets*
  • Blood Preservation*
  • Disinfection* / instrumentation
  • Disinfection* / methods
  • Female
  • Furocoumarins / pharmacology
  • Humans
  • Hydrogen-Ion Concentration
  • Male
  • Time Factors
  • Ultraviolet Rays*

Substances

  • Furocoumarins
  • amotosalen